Association of mortality and endothelial dysfunction with serum ADMA level in COVID-19 patients

Keywords: Asymmetric dimethylarginine, COVID-19, Mortality rate, Endothelial dysfunction, Lymphocyte to albumin ratio

Abstract

Objectives: To investigate the role of asymmetric dimethylarginine (ADMA) level in predicting intensive care and mortality in patients affected with coronavirus disease 2019 (COVID-19).

Methods: This retrospective, cross-sectional study was conducted at Sakarya University Training and Research Hospital (Sakarya, Turkey) between April and August of 2020. We enrolled patients who were diagnosed with COVID-19 via real-time reverse-transcription polymerase chain reaction and admitted to the intensive care (Severe COVID-19; S-COVID) or non intensive care (Moderate COVID-19; M-COVID). We then analyzed the relationship of the ADMA level with various parameters between S-COVID and M-COVID groups.

Results: This study included 87 patients, comprising 43 females and 44 males, with a mean age of 61 and 71.50 years, respectively. The male/female distribution was 22/25 (46.8%/53.2%) in the M-COVID group and 22/18 (55%/45%) in the S-COVID group. The hospitalization time, white blood cell count, neutrophil count, lymphocyte-to-albumin ratio, international normalization ratio, D-dimer, troponin, ferritin, lactate dehydrogenase, C-reactive protein, procalcitonin, erythrocyte sedimentation rate, fibrinogen, lactate, ADMA, and mortality rate were significantly higher (p < 0.05). In contrast, lymphocyte, total cholesterol, high-density lipoprotein, calcium, and albumin values were lower (p < 0.05) in the S-COVID group than in the M-COVID group. While the mortality rate was 55% in S-COVID patients, no mortality was detected in M-COVID patients (p < 0.05). Moreover, ADMA level was 6618 ± 3000 (6400) in S-COVID patients and 5365 ± 3571 (3130) in M-COVID patients, indicating a statistically significant difference (p = 0.012).

Conclusion: The asymmetric dimethylarginine level increases in severe outcomes; hence, it can potentially predict severity in patients with COVID-19.

doi: https://doi.org/10.12669/pjms.38.7.5327

How to cite this:
Karacaer C, Yaylaci S, Demirci T, Cekic D, Suner KO, Cokluk E, et al. Association of mortality and endothelial dysfunction with serum ADMA level in COVID-19 patients. Pak J Med Sci. 2022;38(7):1808-1815. doi: https://doi.org/10.12669/pjms.38.7.5327

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Biographies

Selcuk Yaylacı, Sakarya University Research and Education Hospital, Sakarya, Turkey

Department of Internal Medicine........................................

Taner Demirci, Department of Endocrinology and Metabolism, Sakarya University Research and Education Hospital, Sakarya, Turkey.

Department of Endocrinology and Metabolism,

Published
2022-08-30
How to Cite
Karacaer, C., Yaylacı, S., Demirci, T., Cekic, D., Suner, K. O., Cokluk, E., & Varım, C. (2022). Association of mortality and endothelial dysfunction with serum ADMA level in COVID-19 patients. Pakistan Journal of Medical Sciences, 38(7). https://doi.org/10.12669/pjms.38.7.5327
Section
Original Articles